Neoadjuvant chemotherapy in elderly women with ovarian cancer: Rates of use and effectiveness.

ABSTRACT:

Background

Neoadjuvant chemotherapy (NACT) may reduce perioperative morbidity in women undergoing primary treatment for ovarian cancer. We evaluated patterns of use and outcomes in a population-based cohort of elderly women with ovarian cancer (OC).

Methods

A cohort of patients ≥66 years old diagnosed between 2000 and 2013 with stage III-IV epithelial OC who received surgery and platinum/taxane chemotherapy for primary treatment was identified from the SEER-Medicare database. Propensity-score matching methods were used to examine differences in outcomes. Kaplan-Meier analysis was performed to compare overall survival (OS) in the matched cohort.

Results

From 2000 to 2013, 22.5% of older women received NACT. The use of NACT increased over time from 16% in 2000 to 35.4%

SUBMITTER: Meyer LA 

PROVIDER: S-EPMC8328050 | biostudies-literature | 2018 Sep

REPOSITORIES: biostudies-literature